The US Food and Drug Administration has given Catalyst Pharmaceuticals (Nasdaq: CPRX) approval for Firdapse (amifampridine), a therapy for the rare disease Lambert-Eaton myasthenic syndrome (LEMS).
Shares in the Florida, USA-based firm were boosted nearly 8% in trading on Wednesday. Analysts have forecast that the therapy could ultimately generate annual revenues of over $350 million for the company.
Originally developed by BioMarin Pharmaceutical (Nasdaq: BMRN), the therapy was approved in Europe in 2009 and launched in 2010. Catalyst agreed a licensing deal for North American development in 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze